Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Clin Oncol
मुख्य लेखकों: Kochenderfer, James N., Dudley, Mark E., Kassim, Sadik H., Somerville, Robert P.T., Carpenter, Robert O., Stetler-Stevenson, Maryalice, Yang, James C., Phan, Giao Q., Hughes, Marybeth S., Sherry, Richard M., Raffeld, Mark, Feldman, Steven, Lu, Lily, Li, Yong F., Ngo, Lien T., Goy, Andre, Feldman, Tatyana, Spaner, David E., Wang, Michael L., Chen, Clara C., Kranick, Sarah M., Nath, Avindra, Nathan, Debbie-Ann N., Morton, Kathleen E., Toomey, Mary Ann, Rosenberg, Steven A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Clinical Oncology 2015
विषय:
ORIGINAL REPORTS
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/
https://ncbi.nlm.nih.gov/pubmed/25154820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन